Not So Different: A Trio of Experts on What Needs to Change to Boost Biosimilar Adoption

November 29, 2020


We sat down with a trio of experts to discuss the factors currently impacting biosimilar adoption, what reforms are needed to improve it, and what stakeholders can do to help.

Not So Different: Kathy Oubre on the Benefits of Using Biosimilars in a Community Oncology Practice

November 15, 2020


Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.

Not So Different: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending

November 8, 2020


In an interview with The Center for Biosimilars®, Steven C. Hill, PhD, a senior economist with the Agency for Healthcare Research and Quality, discusses a recent study he co-authored on specialty drug spending.

Not So Different: Nancy Globus, PharmD, on Whether Comparative Efficacy Trials are Necessary

October 25, 2020


We spoke with Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs, for her take on requirements for comparative efficacy trails and whether they add meaningful data for the purposes of biosimilar acceptance.

Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic

October 18, 2020


We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.

Not So Different: Kanika Monga, MD, and Angus Worthing, MD, Discuss ACR Survey on Biosimilars and COVID-19

October 11, 2020


Kanika Monga, MD, of the American College of Rheumatology’s (ACR) Communication and Marketing Committee, and Angus Worthing, MD, an ACR director, discuss the ACR's recent survey on rheumatology.

Wayne Winegarden, PhD, on Downside of Importing Drugs From Canada

October 4, 2020


We sat down with Wayne Winegarden, PhD, a senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI's Center for Medical Economics and Innovation, to discuss why the FDA’s implementation of the Safe Importation Action Plan is controversial.

Not So Different: Julie Kennerly-Shah, PharmD, on How Biosimilars Can Help Curb COVID-19's Impact

September 27, 2020


We sat down with Julie Kennerly-Shah, PharmD, assistant director of Pharmacy at the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute to discuss cost cutting with biosimilars.

Not So Different: Rep Grothman on His Bill to Make Biosimilar Insulins Interchangeable

September 20, 2020


We sat down with Representative Glenn Grothman (R-Wisconsin), the author of HR 8190, a bill that would waive interchangeability requirements for biosimilar insulins, to discuss why this bill is needed for Americans and what it could mean for future biosimilar legislation.

Not So Different: Alex Moulson on How Companies Choose Which Biosimilars to Produce

September 13, 2020


We sat down with Alexandra Moulson, vice president of Strategy, Programs, and Portfolio at Polpharma Biologics to discuss how Polpharma Biologics and other contract development and manufacturing organization (CDMOs) function and how companies choose which molecules to develop.